📊 ENDV Key Takeaways
Is Endonovo Therapeutics, Inc.. (ENDV) a Good Investment?
Endonovo Therapeutics is in severe financial distress with negative stockholders' equity of -$23.0M, indicating the company is technically insolvent. Despite reporting a $8.5M net income anomaly, the company is burning cash at -$407K in free cash flow, has zero liquidity, and minimal revenue of $134.3K cannot support $7.1M in long-term debt and $23.8M in total liabilities.
ENDONOVO THERAPEUTICS shows headline revenue growth, but the business remains fundamentally non-viable on current financials: revenue is immaterial relative to operating losses, free cash flow is deeply negative, and liquidity appears exhausted. The reported net income is not supported by core operations and is likely driven by non-operating accounting effects, while negative equity and a severe working-capital deficit indicate extreme financial stress.
Why Buy Endonovo Therapeutics, Inc.. Stock? ENDV Key Strengths
- Exceptional gross margin of 96.4% indicates strong pricing power on products sold
- Revenue growth of 110.2% YoY shows market demand for offerings
- Minimal capital expenditure needs suggest asset-light business model
- Revenue grew 110.2% year over year, indicating some commercial traction from a very small base
- Gross margin of 96.4% suggests the product mix can be high-margin if scale is achieved
- Capital expenditure is minimal, so cash burn is driven more by operating losses than heavy reinvestment needs
ENDV Stock Risks: Endonovo Therapeutics, Inc.. Investment Risks
- Negative stockholders' equity of -$23.0M represents technical insolvency and existential solvency risk
- Zero cash and equivalents with negative operating cash flow of -$404.4K indicates immediate liquidity crisis
- Revenue of $134.3K cannot service $7.1M long-term debt and $23.8M total liabilities; unsustainable capital structure
- Current ratio and quick ratio of 0.00x confirm complete inability to meet short-term obligations
- Anomalous $8.5M net income amid operational losses suggests one-time gains or accounting adjustments masking underlying distress
- Operating margin of -1589.0% shows the company is nowhere near covering its cost structure
- Cash of $0.00, current ratio of 0.00x, and negative free cash flow indicate acute liquidity and going-concern risk
- Negative stockholders equity of -$22.96M and sizable liabilities versus assets reflect an overleveraged balance sheet
Key Metrics to Watch
- Operating cash flow trend - must turn positive to indicate business viability
- Cash position and liquidity - any additional capital raise or debt restructuring
- Revenue growth sustainability - whether 110% growth can accelerate to meaningful absolute levels ($1M+)
- Stockholders' equity path to positive - requires sustained profitability or capital injection
- Quarterly revenue growth relative to operating expense growth
- Cash balance, operating cash flow, and any improvement in working capital or stockholders equity
Endonovo Therapeutics, Inc.. (ENDV) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
ENDV Profit Margin, ROE & Profitability Analysis
ENDV vs Healthcare Sector: How Endonovo Therapeutics, Inc.. Compares
How Endonovo Therapeutics, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Endonovo Therapeutics, Inc.. Stock Overvalued? ENDV Valuation Analysis 2026
Based on fundamental analysis, Endonovo Therapeutics, Inc.. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Endonovo Therapeutics, Inc.. Balance Sheet: ENDV Debt, Cash & Liquidity
ENDV Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Endonovo Therapeutics, Inc..'s revenue has grown significantly by 63% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.05 indicates the company is currently unprofitable.
ENDV Revenue Growth, EPS Growth & YoY Performance
ENDV Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2023 | $1.5K | -$603.4K | $0.00 |
| Q2 2023 | $650 | $2.1M | $0.00 |
| Q1 2023 | $2.3K | -$2.4M | $0.00 |
| Q3 2022 | $7.8K | -$603.4K | $0.00 |
| Q2 2022 | $650 | -$1.3M | $-0.02 |
| Q1 2022 | $2.3K | -$2.4M | $-0.03 |
| Q3 2021 | $7.8K | -$1.1M | $-0.02 |
| Q2 2021 | $30.3K | -$1.3M | $-0.02 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Endonovo Therapeutics, Inc.. Dividends, Buybacks & Capital Allocation
ENDV SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Endonovo Therapeutics, Inc.. (CIK: 0001528172)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ENDV
What is the AI rating for ENDV?
Endonovo Therapeutics, Inc.. (ENDV) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 96% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ENDV's key strengths?
Claude: Exceptional gross margin of 96.4% indicates strong pricing power on products sold. Revenue growth of 110.2% YoY shows market demand for offerings. ChatGPT: Revenue grew 110.2% year over year, indicating some commercial traction from a very small base. Gross margin of 96.4% suggests the product mix can be high-margin if scale is achieved.
What are the risks of investing in ENDV?
Claude: Negative stockholders' equity of -$23.0M represents technical insolvency and existential solvency risk. Zero cash and equivalents with negative operating cash flow of -$404.4K indicates immediate liquidity crisis. ChatGPT: Operating margin of -1589.0% shows the company is nowhere near covering its cost structure. Cash of $0.00, current ratio of 0.00x, and negative free cash flow indicate acute liquidity and going-concern risk.
What is ENDV's revenue and growth?
Endonovo Therapeutics, Inc.. reported revenue of $134.3K.
Does ENDV pay dividends?
Endonovo Therapeutics, Inc.. does not currently pay dividends.
Where can I find ENDV SEC filings?
Official SEC filings for Endonovo Therapeutics, Inc.. (CIK: 0001528172) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ENDV's EPS?
Endonovo Therapeutics, Inc.. has a diluted EPS of $0.00.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is ENDV a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Endonovo Therapeutics, Inc.. has a STRONG SELL rating with 96% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is ENDV stock overvalued or undervalued?
Valuation metrics for ENDV: ROE of N/A (sector avg: 15%), net margin of 6,351.8% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy ENDV stock in 2026?
Our dual AI analysis gives Endonovo Therapeutics, Inc.. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is ENDV's free cash flow?
Endonovo Therapeutics, Inc..'s operating cash flow is $-404.4K, with capital expenditures of $2.6K. FCF margin is -303.1%.
How does ENDV compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 6,351.8% (avg: 12%), ROE N/A (avg: 15%), current ratio 0.00 (avg: 2).